Group One Trading
IMDX

Group One Trading’s Insight Molecular Diagnostics IMDX Stock Holding History

Group One Trading’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$328 Buy
+100
New +$581 ﹤0.01% 7361
2022
Q2 		– Sell
-35
Closed -$1K – 8292
2022
Q1 		$1K Sell
35
-960
-96% -$30.7K ﹤0.01% 7850
2021
Q4 		$43K Buy
995
+120
+14% +$6.9K ﹤0.01% 6451
2021
Q3 		$62K Buy
875
+255
+41% +$23.4K ﹤0.01% 6361
2021
Q2 		$71K Sell
620
-675
-52% -$65.9K ﹤0.01% 6278
2021
Q1 		$134K Sell
1,295
-80
-6% -$7.6K ﹤0.01% 5388
2020
Q4 		$66K Buy
+1,375
New +$50.4K ﹤0.01% 4831
2019
Q3 		– Sell
-505
Closed -$25K – 5423
2019
Q2 		$25K Buy
+505
New +$42K ﹤0.01% 4076

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Group One Trading's IMDX Position: Q2 2023 in Review

Group One Trading sold out of Insight Molecular Diagnostics (IMDX) in Q2 2023, closing a stake of 1 share — an estimated $9 sold.

Group One Trading first reported a position in IMDX in Q1 2016 and held it in 27 quarters. The position peaked at $64K in Q1 2021. 47 funds tracked by Wall St. Rank hold IMDX as of Q2 2023.

  • Group One Trading reported no remaining Insight Molecular Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Group One Trading sold 1 Insight Molecular Diagnostics share in Q2 2023, an estimated $9.
  • Group One Trading first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 27 quarters.
  • Group One Trading's Insight Molecular Diagnostics position peaked at $64K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2023.

Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.